Display options
Cite
Carr TH, Adelman C, Barnicle A, et al. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers (Basel). 2021;13(22)doi: 10.3390/cancers13225830.
Carr, T. H., Adelman, C., Barnicle, A., Kozarewa, I., Luke, S., Lai, Z., Hollis, S., Dougherty, B., Harrington, E. A., Kang, J., Saad, F., Sala, N., Thiery-Vuillemin, A., Clarke, N. W., Hodgson, D., & Barrett, J. C. (2021). Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers, 13(22), . https://doi.org/10.3390/cancers13225830
Carr, T Hedley, et al. "Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer." Cancers vol. 13,22 (2021). doi: https://doi.org/10.3390/cancers13225830
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers (Basel). 2021 Nov 20;13(22). doi: 10.3390/cancers13225830. PMID: 34830984; PMCID: PMC8616430.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Nov 20;13(22). doi: 10.3390/cancers13225830.

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.

Cancers

T Hedley Carr, Carrie Adelman, Alan Barnicle, Iwanka Kozarewa, Sally Luke, Zhongwu Lai, Sally Hollis, Brian Dougherty, Elizabeth A Harrington, Jinyu Kang, Fred Saad, Nuria Sala, Antoine Thiery-Vuillemin, Noel W Clarke, Darren Hodgson, J Carl Barrett

Affiliations

  1. AstraZeneca, Cambridge CB4 0WG, UK.
  2. AstraZeneca, Boston, MA 43183, USA.
  3. AstraZeneca, Gaithersburg, MD 20878, USA.
  4. University of Montreal Hospital Research Centre, Montreal, QC H4A 3J1, Canada.
  5. Catalan Institute of Oncology, Hospital Josep Trueta, 17007 Girona, Spain.
  6. Medical Oncology, CHU Besançon, 25000 Besançon, France.
  7. The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

PMID: 34830984 PMCID: PMC8616430 DOI: 10.3390/cancers13225830

Abstract

BACKGROUND: Phase III randomized trial data have confirmed the activity for olaparib in homologous recombination repair (HRR) mutated metastatic castration-resistant prostate cancer (mCRPC) post next-generation hormonal agent (NHA) progression. Preclinical data have suggested the potential for a combined effect between olaparib and NHAs irrespective of whether an HRR gene alteration was present. NCT01972217 was a randomised double-blind Phase II study which evaluated olaparib and abiraterone versus placebo and abiraterone in mCRPC patients who had received prior chemotherapy containing docetaxel. The study showed that radiologic progression was significantly delayed by the combination of olaparib and abiraterone regardless of homologous recombination repair mutation (HRRm) status. The study utilized tumour, blood (germline), and circulating tumour DNA (ctDNA) analysis to profile patient HRRm status, but tumour tissue provision was not mandated, leading to relatively low tissue acquisition and DNA sequencing success rates not representative of real-world testing.

PATIENTS AND METHODS: Further analysis of germline and ctDNA samples has been performed for the trial to characterize HRRm status more fully and robustly analyse patient response to treatment.

RESULTS: Germline and plasma testing increased the HRRm characterized population from 27% to 68% of 142 randomized patients. Tumour-derived variants were detectable with high confidence in 78% of patients with a baseline plasma sample (71% of randomized patients). There was high concordance across methodologies (plasma vs. tumour; plasma vs. germline). The HR for the exploratory analysis of radiographic progression-free survival was 0.54 (95% CI: 0.32-0.93) in favour of olaparib and abiraterone in the updated HRR wild type (HRRwt) group (

CONCLUSION: Our results confirm the value of plasma testing for HRRm status when there is insufficient high-quality tissue for multi-gene molecular testing. We show that patients with mCRPC benefit from the combination of olaparib and abiraterone treatment regardless of HRRm status. The combination is currently being further investigated in the Phase III PROpel trial.

Keywords: PARP inhibition; circulating tumour DNA (ctDNA); homologous recombination repair (HRR); metastasis; next-generation sequencing (NGS); prostate cancer

References

  1. N Engl J Med. 2020 Dec 10;383(24):2345-2357 - PubMed
  2. Eur Urol. 2020 Nov;78(5):671-679 - PubMed
  3. Nature. 2005 Apr 14;434(7035):917-21 - PubMed
  4. N Engl J Med. 2011 May 26;364(21):1995-2005 - PubMed
  5. Sci Transl Med. 2015 Nov 4;7(312):312re11 - PubMed
  6. Lancet Oncol. 2018 Jul;19(7):975-986 - PubMed
  7. Sci Transl Med. 2016 Oct 26;8(362):362ps17 - PubMed
  8. Cancer Discov. 2013 Nov;3(11):1245-53 - PubMed
  9. J Clin Oncol. 2015 Jan 20;33(3):244-50 - PubMed
  10. N Engl J Med. 2019 Jul 25;381(4):317-327 - PubMed
  11. Mol Cell. 2015 Nov 19;60(4):547-60 - PubMed
  12. Science. 2006 Jun 23;312(5781):1798-802 - PubMed
  13. J Mol Diagn. 2018 Sep;20(5):686-702 - PubMed
  14. Nat Commun. 2017 Aug 29;8(1):374 - PubMed
  15. Nat Biotechnol. 2013 Nov;31(11):1023-31 - PubMed
  16. N Engl J Med. 2018 Dec 27;379(26):2495-2505 - PubMed
  17. Nat Cancer. 2020 Nov;1(11):1041-1053 - PubMed
  18. J Clin Invest. 2020 Apr 1;130(4):1743-1751 - PubMed
  19. N Engl J Med. 2017 Aug 10;377(6):523-533 - PubMed
  20. J Mol Diagn. 2019 Jul;21(4):646-657 - PubMed
  21. Cancer Discov. 2012 Dec;2(12):1134-49 - PubMed
  22. N Engl J Med. 2020 May 28;382(22):2091-2102 - PubMed

Publication Types

Grant support